Treatment and diagnosis of melanoma

1. A method of treating ovarian cancer in a subject in need thereof, the method comprising administering to the subject an LXRβ agonist selected from:

or a pharmaceutically acceptable salt thereof in an amount sufficient to suppress the invasion of surrounding tissue by the ovarian cancer and/or suppress metastatic colonization of the ovarian cancer.

2. The method of claim 1 , wherein the LXRβ agonist is compound 1, or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the LXRβ agonist is compound 2, or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the LXRβ agonist is compound 12, or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the LXRβ agonist is compound 25, or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the ovarian cancer is resistant to platinum-containing chemotherapy, a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, an antimitotic agent, a topoisomerase inhibitor, an antimetabolite, an angiogenesis inhibitor, a kinase inhibitor, and/or an alkylating agent.

7. The method of claim 6 , wherein the ovarian cancer progressed on or after treatment with platinum-containing chemotherapy, a PD-1 inhibitor, a PD-L1 inhibitor, an angiogenesis inhibitor, a kinase inhibitor, and/or an alkylating agent.

8. The method of claim 6 , wherein the ovarian cancer has been determined to be, or is predicted to be, resistant to a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a topoisomerase inhibitor, an antimetabolite, an angiogenesis inhibitor, a kinase inhibitor, and/or an alkylating agent.

9. The method of claim 1 , wherein the method does not comprise further concurrently administering to the subject an antiproliferative agent.

10. The method of claim 1 , wherein the method further comprises administration of an additional anticancer therapy.

11. The method of claim 10 , wherein the additional anticancer therapy is an immunomodulator, a topoisomerase inhibitor, an antimetabolite, an angiogenesis inhibitor, a kinase inhibitor, and/or an alkylating agent.

12. The method of claim 11 , wherein the immunomodulator is a PD-1 inhibitor, a CTLA4 inhibitor, and/or a PDL1 inhibitor.

13. The method of claim 11 , wherein the antimitotic agent is paclitaxel or docetaxel.

14. The method of claim 11 , wherein the antimetabolite is gemcitabine.

15. The method of claim 1 , wherein the method comprises the suppression of the invasion of surrounding tissue by the ovarian cancer.

16. The method of claim 1 , wherein the method comprises the suppression of metastatic colonization of the ovarian cancer.

17. The method of claim 16 , wherein the method comprises the suppression of metastatic colonization of the ovarian cancer to the lung and/or the brain.

18. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of an LXRβ agonist selected from:

or a pharmaceutically acceptable salt thereof, subsequent to at least one prior anti-cancer therapy.

19. The method of claim 18 , wherein the cancer is breast cancer, colon cancer, renal cell cancer, lung cancer, hepatocellular carcinoma, gastric cancer, ovarian cancer, pancreatic cancer, esophageal cancer, prostate cancer, sarcoma, bladder cancer, or melanoma.

20. The method of claim 18 , wherein the prior anti-cancer therapy is surgery, radiation therapy, and/or chemotherapy.

21. The method of claim 20 , wherein the prior anti-cancer therapy is surgery.

22. The method of claim 20 , wherein the prior anti-cancer therapy is radiation therapy.

23. The method of claim 18 , the method further comprising administering to the subject an additional therapeutic agent.

24. The method of claim 23 , wherein the additional therapeutic agent is an immunomodulator, a topoisomerase inhibitor, an antimetabolite, an angiogenesis inhibitor, a kinase inhibitor, and/or an alkylating agent.

25. The method of claim 24 , wherein the immunomodulator is a PD-1 inhibitor, a CTLA4 inhibitor, and/or a PDL1 inhibitor.

26. The method of claim 18 , wherein the cancer is metastatic cancer.

27. The method of claim 26 , wherein the cancer has been diagnosed as metastatic.

28. The method of claim 18 , wherein the method comprises the suppression of the progression or metastasis of cancer.

29. The method of claim 18 , wherein the compound is compound 1.

30. The method of claim 18 , wherein the compound is compound 2.

31. The method of claim 18 , wherein the compound is compound 12.

32. The method of claim 18 , wherein the compound is compound 25.

33. The method of claim 18 , wherein the cancer is resistant to platinum-containing chemotherapy, a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, an antimitotic agent, a topoisomerase inhibitor, an antimetabolite, an angiogenesis inhibitor, a kinase inhibitor, and/or an alkylating agent.

34. The method of claim 18 , wherein the cancer progressed on or after treatment with platinum-containing chemotherapy, a PD-1 inhibitor, a PD-L1 inhibitor, an angiogenesis inhibitor, a kinase inhibitor, and/or an alkylating agent.

35. The method of claim 18 , wherein the cancer has been determined to be, or is predicted to be, resistant to a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a topoisomerase inhibitor, an antimetabolite, an angiogenesis inhibitor, a kinase inhibitor, and/or an alkylating agent.

36. A method of treating small cell carcinoma in a subject in need thereof, the method comprising administering to the subject an LXRβ agonist selected from:

or a pharmaceutically acceptable salt thereof in an amount sufficient to suppress the invasion of surrounding tissue by the small cell carcinoma and/or suppress metastatic colonization of the small cell carcinoma, wherein the small cell carcinoma is lung cancer or prostate cancer.

37. The method of claim 36 , wherein the LXRβ agonist is compound 1, or a pharmaceutically acceptable salt thereof.

38. The method of claim 36 , wherein the LXRβ agonist is compound 2, or a pharmaceutically acceptable salt thereof.

39. The method of claim 36 , wherein the LXRβ agonist is compound 12, or a pharmaceutically acceptable salt thereof.

40. The method of claim 36 , wherein the LXRβ agonist is compound 25, or a pharmaceutically acceptable salt thereof.

41. The method of claim 36 , wherein the small cell carcinoma is resistant to platinum-containing chemotherapy, a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, an antimitotic agent, a topoisomerase inhibitor, an antimetabolite, an angiogenesis inhibitor, a kinase inhibitor, and/or an alkylating agent.

42. The method of claim 41 , wherein the small cell carcinoma progressed on or after treatment with a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a kinase inhibitor, and/or an alkylating agent.

43. The method of claim 41 , wherein the small cell carcinoma has been determined to be, or is predicted to be, resistant to a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a topoisomerase inhibitor, an antimetabolite, an angiogenesis inhibitor, a kinase inhibitor, and/or an alkylating agent.

44. The method of claim 36 , wherein the method does not comprise further concurrently administering to the subject an antiproliferative agent.

45. The method of claim 36 , wherein the method further comprises administration of an additional anticancer therapy.

46. The method of claim 45 , wherein the additional anticancer therapy is an immunomodulator, a topoisomerase inhibitor, an antimetabolite, an angiogenesis inhibitor, a kinase inhibitor, and/or an alkylating agent.

47. The method of claim 46 , wherein the immunomodulator is a PD-1 inhibitor, a CTLA4 inhibitor, and/or a PDL1 inhibitor.

48. The method of claim 46 , wherein the antimitotic agent is paclitaxel or docetaxel.

49. The method of claim 46 , wherein the antimetabolite is gemcitabine.

50. The method of claim 36 , wherein the method comprises the suppression of the invasion of surrounding tissue by the small cell carcinoma.

51. The method of claim 36 , wherein the method comprises the suppression of metastatic colonization of the small cell carcinoma.

52. The method of claim 51 , wherein the method comprises the suppression of metastatic colonization of the small cell carcinoma to the lung and/or the brain.

53. The method of claim 36 , wherein the small cell carcinoma is lung cancer.